piperacillin/tazobactam

drug combination

DBpedia resource is: http://dbpedia.org/resource/Piperacillin/tazobactam

Abstract is: Piperacillin/tazobactam, sold under the brand name Zosyn among others, is a combination medication containing the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. The combination has activity against many Gram-positive and Gram-negative bacteria including Pseudomonas aeruginosa. It is used to treat pelvic inflammatory disease, intra-abdominal infection, pneumonia, cellulitis, and sepsis. It is given by injection into a vein. Common adverse effects include headache, trouble sleeping, rash, nausea, constipation, and diarrhea. Serious adverse effects include Clostridium difficile infection and allergic reactions including anaphylaxis. Those who are allergic to other β-lactam are more likely to be allergic to piperacillin/tazobactam. Use in pregnancy or breastfeeding appears to generally be safe. It usually results in bacterial death through blocking their ability to make a cell wall. Piperacillin/tazobactam was approved for medical use in the United States in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

C₃₃H₃₉N₉O₁₂S₂

piperacillin/tazobactam is …
instance of (P31):
type of mixture of chemical entitiesQ119892838

sublass of (P279):
combination drugQ1779868

External links are
P233canonical SMILESCCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O.CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
P231CAS Registry Number123683-33-0
P592ChEMBL IDCHEMBL436129
P661ChemSpider ID8094523
P3117DSSTox substance IDDTXSID80894106
P9635electronic Essential Medicines List medicine ID320
P646Freebase ID/m/073q02
P234InChIInChI=1S/C23H27N5O7S.C10H12N4O5S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);2-3,7-8H,4-5H2,1H3,(H,16,17)/t13-,14-,15+,20-;7-,8+,10+/m11/s1
P235InChIKeyLITBAYYWXZOHAW-XDZRHBBOSA-N
P2017isomeric SMILESCCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
P10245MedlinePlus drug identifiera694003
P486MeSH descriptor IDD000077725
P672MeSH tree codeD02.065.589.099.750.687.750.500
D02.065.589.099.750.750.050.650.500
D02.886.108.750.687.750.500
D02.886.108.750.750.050.650.500
D02.886.590.841.500
D03.633.100.300.750.687.750.500
D03.633.100.300.750.750.050.650.500
D26.310.625
P6366Microsoft Academic ID2777858937
P662PubChem CID9918881
P2877SureChEMBL IDSCHEMBL1325039
P4527UK Parliament thesaurus ID438784
P11089UniChem compound ID520235
P11143WikiProjectMed IDPiperacillin/tazobactam

P2067mass817.21596
P3489pregnancy categoryUS pregnancy category BQ28123616
P2868subject has roleessential medicineQ35456
P12081WHO Aware ClassificationwatchQ122925721

Wikimedia Commons Images

P6802: related image


FileName: Piptazo.jpg

Description: A bottle of piperacillin tazobactam

Artist: James Heilman, MD

Work is copyrighted.
License: CC BY-SA 4.0
Attribution is required.

Reverse relations

main subject (P921)
Q593339591067. Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive Staphylococcus aureus Bacteremia
Q941219511149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
Q593279021414. Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes
Q593337721416. Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability?
Q941288592166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip
Q941422282244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
Q941415222292. Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy
Q941428972385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
Q593342452407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp
Q593284092432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
Q593280222436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
Q593273482442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
Q941415172687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
Q94133410400. Comparison of Tolerance and Microbiological Efficacy of Cefepime and Piperacillin/Tazobactam in Combination with Vancomycin as Empirical Antimicrobial Therapy of Prosthetic Joint Infection: A Propensity-Matched Cohort Study
Q100514715A Much-Anticipated Leap Forward in β-Lactam Drug Allergy: Phenotyping Reactions to Piperacillin/Tazobactam
Q98390736A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Q90284827A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patient
Q45274805A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis
Q44270987A multicenter clinical trial of piperacillin/tazobactam in burn infection
Q71654587A multicentre in vitro evaluation of piperacillin/tazobactam in Germany
Q33438606A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam
Q53668374A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Q73465204A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections
Q72956657A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group
Q35328383A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections
Q72826433A reminder: piperacillin/tazobactam is not for Pseudomonas
Q57728123A validated LC–MS/MS method for the quantification of piperacillin/tazobactam on dried blood spot
Q39929915Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Q54034077Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Q54342220Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Q50124154Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime
Q37097893Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
Q90541009Acute eosinophilic pneumonia due to piperacillin/tazobactam
Q88646537Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis
Q40195923Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function
Q87029822Acute localized exanthematous pustulosis on inguinal area secondary to piperacillin/tazobactam
Q44732727Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia
Q91135287Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae
Q73328451An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected
Q71354387An evaluation of the in vitro activity of piperacillin/tazobactam
Q43758478An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone
Q53989640An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections.
Q44294929An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers
Q79986962Antibacterial activity of tazocin (piperacillin/tazobactam) against 1296 clinical isolates from a tertiary care center
Q79385930Antibiotic prophylaxis in hernia repair and breast surgery: a prospective randomized study comparing piperacillin/tazobactam versus placebo
Q43263131Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Q60198307Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms
Q47230552Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections
Q40424803Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia
Q99726946Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow
Q101237853Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study
Q41991618Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children
Q35100125Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review
Q45911239Balancing the Efficacy and Safety of Implementing a Piperacillin/tazobactam (PTZ) Antibiotic Time-out.
Q54232073Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
Q60922047Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible : A Missed Opportunity for De-Escalation of Therapy
Q70493359Breakpoint determination: piperacillin/tazobactam
Q42201138Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis
Q40312112Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward
Q44176569Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa
Q47164903Cefoxitin vs. Piperacillin/Tazobactam for Acute Appendicitis in Pediatric Patients
Q64947381Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort.
Q34520874Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center
Q100644011Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital
Q40078698Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Q85924935Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam
Q46159338Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion
Q40388018Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy
Q39382608Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections
Q91991786Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem
Q37642084Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial
Q34892334Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis
Q38052888Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis
Q102322061Combination therapy of vancomycin and piperacillin/tazobactam in adult febrile neutropenia patients with haematopoietic malignancies increases the risk of acute kidney injury regardless of vancomycin trough concentration
Q71624486Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination
Q91693359Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection
Q79399849Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype
Q44604885Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North Ame
Q59386991Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients
Q54123202Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Q73732060Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam
Q33542819Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study
Q71861334Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli
Q73888005Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital
Q90918948Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy
Q33508983Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients
Q33508985Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients
Q43994172Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Q40601273Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)
Q40852055Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria
Q91566126Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria
Q41513406Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study
Q57773615Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections
Q91260328Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit
Q67505982Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam
Q46951637Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
Q50015025Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study
Q44021739Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Q96607569Concomitant vancomycin and piperacillin/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients
Q38208157Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Q34490565Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.
Q82876738Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs
Q40948657Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
Q91327246Corrigendum to "Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study" [Journal of Critical Care 52 (2019) 75-79]
Q42953644Cost-Effectiveness Evaluation of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Accounting for Antibiotic Resistance
Q33617939Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
Q40203385Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Q45351595Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance da
Q74619018Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective
Q35650111Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics
Q40344887Delayed-type hypersensitivity reaction to piperacillin/tazobactam in a patient with an infected total knee replacement
Q44855148Determination of nontoxic concentrations of piperacillin/tazobactam for intravitreal application. An electroretinographic, histopathologic and morphometric analysis
Q44047336Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder
Q50066986Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Q42607392Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care h
Q35993212Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
Q38848103Dose optimization of piperacillin/tazobactam in critically ill children.
Q82744390Dosing of piperacillin/tazobactam in a morbidly obese patient
Q36299254Drug Fever Induced by Piperacillin/Tazobactam in a Scoliosis Patient: A Case Report
Q34540020Drug fever due to piperacillin/tazobactam loaded into bone cement
Q40095824Drug fever induced by piperacillin/tazobactam in an elderly patient with underlying human immunodeficiency virus (HIV) infection
Q91077960Drug utilization evaluation of Piperacillin/Tazobactam: A prospective and cross sectional investigation in tertiary care setup
Q64128953Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study
Q50928065Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong.
Q38675320Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure
Q67493290Effect of piperacillin/tazobactam therapy on intestinal microflora
Q44821677Effect of piperacillin/tazobactam treatment on human bowel microflora
Q45020548Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa
Q44930306Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers
Q38939632Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital
Q40658654Effectiveness of piperacillin/tazobactam in the treatment of fever of unknown etiology in patients with granulocytopenia
Q101475452Effects of Antibiotic Treatment with Piperacillin/Tazobactam versus Ceftriaxone on the Composition of the Murine Gut Microbiota
Q46462987Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
Q36592698Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study
Q94701669Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study
Q71654600Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections
Q40393949Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections
Q44416621Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia.
Q43609282Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial
Q40571303Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation
Q71654593Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections
Q46843092Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis
Q72956661Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
Q53946960Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Q43815756Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure
Q90039422Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study
Q80794429Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation
Q54367468Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
Q34468030Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Q40786989Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial
Q33516983Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
Q35057515Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Q37978466Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review
Q38162192Evaluating the appropriate use of piperacillin/tazobactam in a community health system: a retrospective chart review
Q38925943Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
Q37250189Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.
Q97674932Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients
Q40755351Evaluation of the use of piperacillin/tazobactam (Tazocin) at Hamad General Hospital, Qatar: are there unjustified prescriptions?
Q43263134Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots
Q38714853Extended Infusion of Piperacillin/Tazobactam in Children
Q38442491Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy
Q72170451FDA approved new drug bulletin: piperacillin/tazobactam (zosyn), salmeterol xinafoate (serevent)
Q81454293False positivity for Aspergillus antigenemia related to the administration of piperacillin/tazobactam
Q46468471False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem?
Q91295843False-positive results in the galactomannan Platelia™ Aspergillus assay with generic piperacillin/tazobactam
Q95582370Generalized fixed drug eruption to piperacillin/tazobactam and review of literature
Q41038249Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.
Q88900133HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam
Q45418219Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology
Q73831010High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital
Q64990162Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study.
Q40219976Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units
Q45049839Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis
Q40243248Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults.
Q40505651Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study
Q33503896Immune thrombocytopenia caused by piperacillin/tazobactam
Q58581078Impact of Piperacillin/Tazobactam on Nephrotoxicity in Patients with Gram-negative Bacteremia
Q41243978Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis
Q40922179Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
Q41873335In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa
Q60169867In vitro Activity of Piperacillin/Tazobactam against 615 Pseudomonas aeruginosa Strains Isolated in Intensive Care Units
Q81605655In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials
Q70816336In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals
Q54441193In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Q42167822In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles
Q74788485In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients
Q73153134In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams
Q54365696In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Q46789907In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
Q72797160In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents
Q42769136In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-type β-lactamases
Q87536760In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem
Q39092509In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Q77438097In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates
Q73097378In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin
Q94675843Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study
Q33335393Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study
Q98665337Incidence of Acute Kidney Injury Among Infants in the Neonatal Intensive Care Unit Receiving Vancomycin With Either Piperacillin/Tazobactam or Cefepime
Q93120550Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime
Q41987133Increasing evidence of the nephrotoxicity of piperacillin/tazobactam and vancomycin combination therapy - what is the clinician to do?
Q91719543Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?
Q91709633Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae
Q31061843Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis
Q45221743Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration
Q44383757Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum
Q89597706Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
Q45289238Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Q42920211Intravenous piperacillin/tazobactam plus fluoroquinolone prophylaxis prior to prostate ultrasound biopsy reduces serious infectious complications and is cost effective
Q42791503Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis
Q92746142Invasive paediatric Elizabethkingia meningoseptica infections are best treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or fluoroquinolone
Q46904818Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains
Q80008085Is Tazocin (piperacillin/tazobactam) effective against non -lactamase producers?
Q40470332Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien
Q80192309Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis
Q84758162Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report
Q46011351Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
Q89502917Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model
Q33331121Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis
Q71114846Life-threatening neutropenia secondary to piperacillin/tazobactam therapy
Q40364811Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial
Q33751132Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Q101556873Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day
Q40142656Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients
Q41205767Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis
Q54358083Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
Q38070907Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure
Q40484723Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison
Q77054783Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
Q86380443More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA
Q90039419Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam
Q43859139Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections
Q72570621Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles
Q38511099Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature
Q99566393Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
Q101359589Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams
Q92771866Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study
Q50003909Ocular Permeation of Topical Tazocin and Its Effectiveness in the Treatment of Pseudomonas aeruginosa Induced Keratitis in Rabbits
Q40539790Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia
Q80614476Optimising piperacillin/tazobactam dosing in paediatrics
Q92698139Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems
Q45981027Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Q92863127PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA
Q95516465Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study
Q43916920Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue
Q36624535Penetration of piperacillin/tazobactam into gynecologic tissues following a single loading dose prior to hysterectomy
Q49428641Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients.
Q96681463Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae
Q52231066Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
Q44176576Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis
Q46609027Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms
Q46122902Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections
Q72811534Pharmacokinetic characteristics of piperacillin/tazobactam
Q58424135Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate
Q44569224Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 20
Q51796852Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Q40810754Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock
Q44104691Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing
Q40393943Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections
Q53912120Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.
Q34462071Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
Q49166528Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment
Q37889386Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.
Q36625129Piperacillin/Tazobactam (ZOSYN)
Q90001946Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children
Q92619569Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
Q44194550Piperacillin/Tazobactam inducing seizures in a hemodialysed patient
Q92416136Piperacillin/Tazobactam versus Tobramycin-Based Antibiotic Prophylaxis for Type III Open Fractures
Q43802907Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
Q40471195Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination
Q34096531Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential
Q83881387Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay
Q69364580Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains
Q42260223Piperacillin/tazobactam Induced Myelosuppression.
Q93608433Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia
Q68488621Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae
Q40440027Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study
Q73113195Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections
Q72574046Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection
Q54736676Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in target plasma-concentrations.
Q71728536Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections
Q54631175Piperacillin/tazobactam in complicated urinary tract infections.
Q54146587Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Q72811538Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review
Q40670277Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial
Q42595403Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group
Q54200566Piperacillin/tazobactam in the treatment of polymicrobial infections.
Q68256495Piperacillin/tazobactam in the treatment of serious acute soft tissue infection
Q46962912Piperacillin/tazobactam in treatment of brain abscess
Q33402228Piperacillin/tazobactam induced thrombocytopaenia--a delayed response
Q40326885Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia
Q40419049Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies
Q90743340Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia
Q40393011Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients
Q40729000Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy
Q74629167Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients
Q53933158Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.
Q100415732Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B
Q99202016Piperacillin/tazobactam selects an ampC derepressed E. cloacae complex mutant in a diabetic osteoarticular infection
Q74445707Piperacillin/tazobactam therapy for diabetic foot infection
Q44206071Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Q40388224Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study
Q40329901Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia
Q43260800Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital
Q72951194Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
Q74683283Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital
Q90293380Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review
Q40489194Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial
Q79803938Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study
Q40222930Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases
Q41125741Piperacillin/tazobactam: a critical review of the evolving clinical literature
Q72956628Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination
Q34458678Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections
Q33649676Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections
Q54348027Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
Q37306664Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
Q90190596Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia
Q41306032Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections
Q46588566Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection
Q45308970Population pharmacokinetics of piperacillin/tazobactam in critically ill young children
Q42684527Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants
Q40186288Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia
Q44019734Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections
Q46530464Preliminary study on the release of DNA from Pseudomona aeruginosa induced by piperacillin/tazobactam in vitro
Q38245389Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Q40520288Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia
Q44852610Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan
Q34729874Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.
Q33551807Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam
Q34687596Proteomic changes in Bacteroides fragilis exposed to subinhibitory concentration of piperacillin/tazobactam
Q45162945Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection
Q54444593Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Q44707193Randomized, prospective and comparative clinical trial of piperacillin/tazobactam versus ceftriaxone plus ornidazole in the treatment of biliary tract infections
Q34547453Rash associated with piperacillin/tazobactam administration in infectious mononucleosis
Q44665006Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy
Q80008077Reply: Is Tazocin (piperacillin/tazobactam) effective against non -lactamase producers?
Q77747857Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam
Q92614468Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1
Q50802868Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
Q71654604Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group
Q54200563Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.
Q35811642Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy
Q104682639Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin
Q40306703Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli
Q96016944Safety and tolerability of i.v. push piperacillin/tazobactam within an emergency department
Q44951211Safety evaluation of piperacillin/tazobactam in very low birth weight infants
Q90678063Safety of Subcutaneous Piperacillin/Tazobactam Administration Compared to Intravenous Administration: Propensity Score-Matched Cohort Study
Q72956643Safety profile of piperacillin/tazobactam in phase I and III clinical studies
Q47213579Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study
Q44845058Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa
Q40179593Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual
Q89972654Severe acute hypokalaemia associated with piperacillin/tazobactam in an HIV-infected patient under antiretroviral therapy with tenofovir alafenamide: case report and literature review
Q33408895Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam
Q46638787Shelf lives of aseptically prepared medicines--stability of piperacillin/tazobactam in PVC and non-PVC bags
Q96645009Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients
Q50089280Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function
Q40160630Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots ( Amazona ventralis ).
Q89507243Stability of Meropenem and Piperacillin/Tazobactam with Heparin in Various Peritoneal Dialysis Solutions
Q39212088Stability of aseptically prepared tazocin solutions in polyvinyl chloride bags
Q43281923Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients
Q44825035Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia
Q35891315Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates
Q50358121Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection.
Q84244202Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010)
Q72570609Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam
Q54130681Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Q42388733Suspected drug reaction with piperacillin/tazobactam, in a premature infant
Q91664395Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
Q46263829System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective
Q38819770Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants
Q47373329Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study
Q85962587Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers
Q87972559The Cost of Vancomycin and Piperacillin/Tazobactam Treatment
Q54261702The Cost of Vancomycin and Piperacillin/Tazobactam Treatment-Reply.
Q54237274The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Q90573004The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: A systematic review and meta-analysis
Q34325764The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection
Q38819361The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 U.S. medical centers.
Q72956667The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia
Q46533701The efficacy of intravitreal piperacillin/tazobactam in rabbits with experimental Staphylococcus epidermidis endophthalmitis: a comparison with vancomycin
Q46473308The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation
Q46172279The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients
Q44133712The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates
Q44039660The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria
Q43125603The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections
Q72811542The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam
Q44513902The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship
Q31024483The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data
Q92567947Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial
Q93040611Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience
Q72956634Therapy of soft tissue infections with piperacillin/tazobactam
Q96123835Time above the minimum inhibitory concentration of piperacillin/tazobactam as a predictor of outcome in Pseudomonas aeruginosa bacteraemia
Q73508333Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes
Q40641112Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation
Q43087521Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis.
Q34626378Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam
Q72544894Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study
Q92159125Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae
Q43479288Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department
Q98562945Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature
Q44342540Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases
Q42233062Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations
Q41714355Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides
Q61842395[Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections]
Q54214252[Bacteremia by Escherichia coli resistant to amoxycillin/clavulanic acid, ampicillin/sulbactam and piperacillin/tazobactam]
Q73283478[Clinico-laboratory study of piperacillin/tazobactam in the treatment of patients with would infection]
Q94602523[Combinatorial Vancomycin and Piperacillin/Tazobactam Results in Elevated Vancomycin Trough Concentration and Acute Kidney Injury: A Case Report]
Q72143413[Drugs: piperacillin/tazobactam]
Q54573785[Effect of piperacillin/tazobactam on the anti-infection resistance in patients with infections in the peritoneal cavity].
Q87905620[Enterobacteriaceae susceptibility to piperacillin/tazobactam in a Chilean pediatric hospital]
Q54112263[Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Q101238477[Investigation of Pseudomonas aeruginosa Biofilm Formation and Quorum Sensing Genes in Piperacillin/Tazobactam and Ciprofloxacin Sub-minimal Inhibitory Concentrations]
Q104800702[Pharmacokinetics and therapeutic monitoring of piperacillin/tazobactam]
Q53715745[Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital].
Q73283473[Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis]
Q98775245[Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis]
Q91581759[Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study]
Q53739006[Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae].

Q37155World Health Organization Model List of Essential Medicineshas part(s)P527

The articles in Wikimedia projects and languages

Arabic (ar / Q13955)https://ar.wikipedia.org/wiki/بيبراسيلين/تازوباكتامwikipedia
      https://en.wikipedia.org/wiki/Piperacillin/tazobactamwikipedia
      https://es.wikipedia.org/wiki/Piperacilina/tazobactamwikipedia
Persian (fa / Q9168)https://fa.wikipedia.org/wiki/پیپراسیلین/تازوباکتامwikipedia
      https://fr.wikipedia.org/wiki/Pipéracilline/tazobactamwikipedia
      https://he.wikipedia.org/wiki/פיפרצילין/טזובקטםwikipedia
      https://hy.wikipedia.org/wiki/Պիպերացիլին/տազոբակտամwikipedia
      ピペラシリン・タゾバクタムwikipedia
orhttps://or.wikipedia.org/wiki/ପିପେରାସିଲିନ/ଟାଜୋବାକ୍ଟମwikipedia
      https://pt.wikipedia.org/wiki/Piperacilina/tazobactamwikipedia
      https://ro.wikipedia.org/wiki/Piperacilină/tazobactamwikipedia
Serbo-Croatian (sh / Q9301)https://sh.wikipedia.org/wiki/Piperacilin/tazobaktamwikipedia
      https://sr.wikipedia.org/wiki/Piperacilin/tazobaktamwikipedia
      https://vi.wikipedia.org/wiki/Piperacillin/tazobactamwikipedia

Search more.